Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

12.92
-0.0450-0.35%
Post-market: 12.88-0.0350-0.27%19:57 EDT
Volume:14.53M
Turnover:186.93M
Market Cap:5.85B
PE:-18.30
High:13.15
Open:12.52
Low:12.31
Close:12.96
52wk High:15.30
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:0.83
T/O Rate:3.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:7.95
PE(LYR):-11.80

Loading ...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 20

BRIEF-Iovance Biotherapeutics Inc Files For Mixed Shelf

Reuters
·
Jun 19

Iovance Biotherapeutics files automatic mixed securities shelf

TIPRANKS
·
Jun 19

Iovance Biotherapeutics Inc: Sale Agreement Prospectus Supplement Covering Offering of up to $89.7 Mln Common Stock

THOMSON REUTERS
·
Jun 19

Iovance Biotherapeutics Inc Files for Mixed Shelf - SEC Filing

THOMSON REUTERS
·
Jun 19

Iovance Biotherapeutics (IOVA) Stock Valuation After Australia’s Conditional Approval Of Amtagvi

Simply Wall St.
·
Jun 15

Iovance says Australia regulator approves Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 11

Iovance’s Australian Amtagvi Nod Adds Test For Valuation Upside

Simply Wall St.
·
Jun 05

BRIEF-Iovance's Amtagvi Granted Approval For Treatment Of Advanced Melanoma In Australia

Reuters
·
Jun 04

Iovance receives Australian approval of Amtagvi for advanced melanoma

TIPRANKS
·
Jun 04

Australia TGA approves Iovance Amtagvi for previously treated advanced melanoma

Reuters
·
Jun 04

Iovance’s Amtagvi® (Lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

THOMSON REUTERS
·
Jun 04

Iovance’s Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia

GlobeNewswire
·
Jun 04

Iovance gets allowance to proceed from FDA for IOV-5001 IND application

TIPRANKS
·
Jun 01

Iovance Biotherapeutics Receives US FDA Clearance to Begin IOV-5001 Trial in Solid Tumors

MT Newswires Live
·
Jun 01

Iovance says FDA clears IND for IL-12 tethered TIL therapy IOV-5001

Reuters
·
Jun 01

Iovance Biotherapeutics Announces Clearance of Investigational New Drug (Ind) Application for Il-12 Tethered Til Therapy Iov-5001

THOMSON REUTERS
·
Jun 01

A Look At Iovance Biotherapeutics (IOVA) Valuation After Recent Share Price Recovery

Simply Wall St.
·
May 31

Iovance grants inducement stock options for 93,340 shares at $3.7 each

Reuters
·
May 23

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
May 23